Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples

Cytometry Part B - Clinical Cytometry

Volumn 88, Issue 1, 2015, Pages 6-20

  Tario, Joseph D ^a   Chen, George L ^a   Hahn, Theresa E ^a   Pan, Dalin ^a   Furlage, Rosemary L ^a   Zhang, Yali ^a   Brix, Liselotte ^b   Halgreen, Charlotte ^b   Jacobsen, Kivin ^b   McCarthy, Philip L ^a   Wallace, Paul K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Immudex   (Denmark)

Author keywords

Antigen specific T cell; Cytomegalovirus; Dextramers; Flow cytometry; Immune monitoring

Indexed keywords

DEXTRAMER; REAGENT; TETRAMER; UNCLASSIFIED DRUG; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; FLUORESCENT DYE; LYMPHOCYTE ANTIGEN RECEPTOR; PHYCOERYTHRIN; T LYMPHOCYTE RECEPTOR; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS ANTIGEN SPECIFIC T CELL; GRAFT RECIPIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; LEUKOCYTE; NONHUMAN; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; BLOOD; CHEMISTRY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FLOW CYTOMETRY; IMMUNOLOGY; MONONUCLEAR CELL; OBSERVER VARIATION; PROCEDURES; STAINING; STANDARDS; VIROLOGY;

ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; INDICATORS AND REAGENTS; LEUKOCYTES, MONONUCLEAR; OBSERVER VARIATION; PHYCOERYTHRIN; RECEPTORS, ANTIGEN, T-CELL; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; T-CELL ANTIGEN RECEPTOR SPECIFICITY;

EID: 84918581232     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21196     Document Type: Article

References (32)

1. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96.
2. Matsui K, Boniface JJ, Reay PA, Schild H, Fazekas De St Groth B, Davis MM. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 1991;254:1788-1791.
3. Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, Chien Y. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol 1998;16:523-544.
4. Wooldridge L, Lissina A, Cole DK, Van Den Berg HA, Price DA, Sewell AK. Tricks with tetramers: How to get the most from multimeric peptide-MHC. Immunology 2009;126:147-164.
5. Bakker AH, Schumacher TN. MHC multimer technology: current status and future prospects. Curr Opin Immunol 2005;17:428-433.
6. Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol 2004;65:416-422.
7. Stocchi R, Ward KN, Fanin R, Baccarani M, Apperley JF. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica 1999;84:71-79.
8. Takenaka K, Gondo H, Tanimoto K, Nagafuji K, Fujisaki T, Mizuno S, Miyamoto T, Okamura T, Hayashi S, Eto T, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1997;19:241-248.
9. Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, Zaia JA, Forman SJ, Gaal K, Bray KR, Gasior GH, et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: A prospective multicenter study. Blood 2010;116:1655-1662.
10. Abate D, Cesaro S, Cofano S, Fiscon M, Saldan A, Varotto S, Mengoli C, Pillon M, Calore E, Biasolo MA, et al. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation 2012;93:536-542.
11. Borchers S, Bremm M, Lehrnbecher T, Dammann E, Pabst B, Wolk B, Esser R, Yildiz M, Eder M, Stadler M, et al. Sequential anticytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS One 2012;7:e50248.
12. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: The national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010;50:1439-1447.
13. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006;43:1143-1151.
14. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990;12(Suppl 7):S701-S710.
15. Yao J, Bechter C, Wiesneth M, Harter G, Gotz M, Germeroth L, Guillaume P, Hasan F, Von Harsdorf S, Mertens T, et al. Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: A comparative study. Clin Infect Dis 2008;46:e96-e105.
16. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-558.
17. Gratama JW, Brooimans RA, Van Der Holt B, Sintnicolaas K, Van Doornum G, Niesters HG, Lowenberg B, Cornelissen JJ. Monitoring cytomegalovirus IE-1 and pp65-specific CD41 and CD81 T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry Part B Clin Cytom 2008;74:211-220.
18. De Jongste AH, De Graaf MT, Van Den Broek PD, Kraan J, Sillevis Smitt PA, Gratama JW. Effector memory and late memory T cells accumulate in the blood of CMV-carrying individuals but not in their cerebrospinal fluid. Cytometry Part B Clin Cytom 2013;84:218-221.
19. Pang XL, Chui L, Fenton J, Le Blanc B, Preiksaitis JK. Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation. J Clin Microbiol 2003;41:3167-3174.
20. Gentile G, Picardi A, Capobianchi A, Spagnoli A, Cudillo L, Dentamaro T, Tendas A, Cupelli L, Ciotti M, Volpi A, et al. A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infect Dis 2006;6:167.
21. Boaretti M, Sorrentino A, Zantedeschi C, Forni A, Boschiero L, Fontana R. Quantification of cytomegalovirus DNA by a fully automated real-time PCR for early diagnosis and monitoring of active viral infection in solid organ transplant recipients. J Clin Virol 2013;56:124-128.
22. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, Goldman J, Craddock C, Moss PA. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001;97:1232-1240.
23. Gratama JW, Van Esser JW, Lamers CH, Tournay C, Lowenberg B, Bolhuis RL, Cornelissen JJ. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD81 T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98:1358-1364.
24. Komanduri KV, St John LS, De Lima M, McMannis J, Rosinski S, McNiece I, Bryan SG, Kaur I, Martin S, Wieder ED, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007;110:4543-4551.
25. Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, Ames S, Lerner S, Ebcioglu Z, Nair V, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010;10:2132-2141.
26. Staley EM, Tanner SM, Daft JG, Stanus AL, Martin SM, Lorenz RG. Maintenance of host leukocytes in peripheral immune compartments following lethal irradiation and bone marrow reconstitution: Implications for graft versus host disease. Transpl Immunol 2013;28:112-119.
27. Shima T, Miyamoto T, Kikushige Y, Mori Y, Kamezaki K, Takase K, Henzan H, Numata A, Ito Y, Takenaka K, et al. Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation. Blood 2013;121:840-848.
28. Le Bourgeois A, Lestang E, Guillaume T, Delaunay J, Ayari S, Blin N, Clavert A, Tessoulin B, Dubruille V, Mahe B, et al. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). Eur J Haematol 2013;90:177-186.
29. Darlington PJ, Touil T, Doucet JS, Gaucher D, Zeidan J, Gauchat D, Corsini R, Kim HJ, Duddy M, Jalili F, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 2013;73:341-354.
30. De Pagter PJ, Boelens JJ, Jacobi R, Schuurman R, Nanlohy NM, Sanders EA, Van Baarle D. Increased proportion of perforin-expressing CD81Tcells indicates control of herpesvirus reactivation in children after stem cell transplantation. Clin Immunol 2013;148:92-98.
31. Ravkov EV, Pavlov IY, Hanson KE, Delgado JC. Validation of cytomegalovirus immune competence assays for the characterization of CD8 (1) T cell responses posttransplant. Clin Dev Immunol 2012;2012:451059.
32. http://www.mblintl.com/support/faq.aspx